

U.S. NUCLEAR REGULATORY COMMISSION

Date: 7/20/11

TELEPHONE CONVERSATION RECORD

Time:

Mail Control
or Report No(s).

N/A

License No(s).

06-08544-01

Docket No(s).

03001274

Name of Licensee: Danbury Hospital

Name of Participant(s): William Johns, M.D., Director of Nuclear Medicine and RSC Chairman

Telephone No. 203-739-7428, william.johns@danhosp.org

Subject: CardioGen rubidium-82 generators

This record represents a series of communications by telephone and e-mail on the above-referenced date.

I contacted Dr. Johns to confirm that his institution received information from Bracco about CardioGen rubidium-82 generators, including QC procedures, possible strontium breakthrough, and reports of possible increased radiation exposure to patients.

Dr. Johns said that his Nuclear Medicine chief technologist received this information from Bracco last Friday and discussed it with technologists involved in CardioGen use. As a result of my call, Dr. Johns reviewed his institution's QA/QC protocol for CardioGen, then informed me that Danbury Hospital has been "following all of the necessary steps described in the information from Bracco." He also said "Our Sr-82 breakthrough has never exceeded the levels indicated, except in the circumstance where we received a defective generator and it was not used."

I provided to Dr. Johns the link to the FDA Drug Safety Communication:

<http://www.fda.gov/Drugs/DrugSafety/ucm263112.htm>

Action Required: Place record into ADAMS.

Document Availability:

Publicly Available

Non-Publicly Available

Non-Sensitive

Sensitive – Privacy Act/ PII

Immediate Release

Non-Sensitive Copyright

Sensitive – Internal

Normal Release Date: 7/28/2011

Sensitive- Proprietary

Sensitive – Security-Related

Delayed Release Date:

SUNSI Review Completed By: S. Gabriel

/ RA /

Document Accession #: ML112010332